In animal studies, mice with glioblastoma that received a nanofiber implant embedded with three cancer-fighting drugs survived twice as long as untreated mice—and 40 percent lived beyond the 120-day length of the experiment. This breakthrough comes from researchers at the University of Cincinnati and Johns Hopkins Medicine, who have developed what may be a turning point in treating one of the brain's most lethal cancers.
Glioblastoma is the most common and aggressive form of brain cancer in adults, and it has long been a clinical nightmare. The disease evolves constantly, mutating to slip past whatever treatment doctors throw at it. "It comes in through the window and when you close the window, it comes through the door," said Andrew Steckl, a Distinguished Research Professor at UC's NanoLab, capturing the cancer's relentless adaptability. The blood-brain barrier, which normally protects the brain from harmful substances, also blocks traditional chemotherapy drugs from reaching tumors effectively. High recurrence rates and treatment resistance have made glioblastoma stubbornly difficult to cure.
The UC and Johns Hopkins team tackled this problem by embedding three federally approved drugs—temozolomide, acriflavine, and PT2385—into an electrospun nanofiber mesh that can be implanted directly at the tumor site during surgery. The innovation lies in what researchers call synergism: when combined, these three drugs work together in ways that are more powerful than the sum of their parts. "When you add them together, three things can happen," Steckl explained. "The combination is negative; the effect is additive, like one plus one equals two; or it's synergistic, which is like one plus one equals three."
Daewoo Han, an assistant professor in UC's College of Engineering and Applied Science and lead author of the study published in ACS Biomaterials Science & Engineering, designed the nanofiber system to deliver drugs precisely where they're needed while protecting the rest of the body from toxic side effects. Because the implant sits directly in the brain, it creates a localized pharmaceutical fortress that the blood-brain barrier cannot block. The system provides both immediate and sustained drug release over time, maximizing the cancer-fighting power while minimizing harm to healthy tissue.
The animal trial results were stark. All untreated mice died within 19 days. In contrast, a majority of mice treated with the three-layer nanofiber mesh survived twice as long, and remarkably, 40 percent lived past day 120, entering a survival plateau that extended for more than 80 days. Those numbers represent the kind of gains that matter in cancer research—meaningful extensions of life and, in some cases, apparent durable control of the disease.
The researchers see this technology as part of a broader shift in cancer treatment. "Cancers know how to pivot to evade therapeutic treatment," said Betty Tyler, a professor of neurosurgery at Johns Hopkins Medicine who collaborated on the work. "So we're approaching treatment multidimensionally." This combination strategy—hitting the cancer from multiple angles at once—reflects the hard-won lesson that single drugs rarely suffice against such adaptable foes.
Han and his team are now optimizing the long-term drug release properties of the nanofiber system using advanced materials science. They envision a future where this technology extends beyond glioblastoma to other difficult-to-treat cancers. "Our ultimate goal is moving forward to a clinically translatable system that improves both survival and quality of life for patients with difficult-to-treat cancers," Han said. The path from mouse models to human patients is long, but this nanofiber implant has opened a door that may soon lead somewhere hopeful.